Purchase Order 36C25922P1322

Award Date 8/18/22
Potential Completion Date 2/28/23
Potential Value $288K
Ultimate Awardee
Cardinal Health, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Dublin, OH 43017, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
<p>The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 8 (VA - VHA) awarded a $287,923.29 purchase order to Cardinal Health, Inc., doing business as Cardinal Health, for YESCARTA Drug. The contract has a period of performance from March 22, 2022 through March 28, 2022 and utilizes a firm fixed price pricing structure. Cardinal Health, Inc. will provide YESCARTA, a chimeric antigen receptor T-cell therapy, as the prime contractor.</p>
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 8 (VA - VHA) awarded a $287,923.29 purchase order to Cardinal Health, Inc., doing business as Cardinal Health, for EMERGENCY-YESCARTA. The prime contractor, Cardinal Health, Inc., a subsidiary of Cardinal Health, will provide the products or services defined in the EMERGENCY-YESCARTA solicitation from their place of performance in Dublin, Ohio, between November 30, 2022 and December 2, 2022. The...
<p>The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 8 (VA - VHA) awarded a $284,904.52 purchase order contract to Cardinal Health, Inc., doing business as Cardinal Health, for YESCART (AXICABTAGENE CILOLEUCEL INJ SUSP). The place of performance is Dublin, OH and the contract period is from November 30, 2021 to December 1, 2021. The pricing structure is firm fixed price. No subcontractors were identified.</p>
This federal contract was awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Cardinal Health, Inc. for the delivery of one treatment of the cancer drug YESCARTA. The contract has a firm fixed price of $284,904.52 and a completion date of May 28, 2021. As the prime contractor, Cardinal Health will leverage its expertise in nuclear pharmacy services and distribution capabilities to ensure reliable delivery of this essential radiopharmaceutical product to the VA...
<p>The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 8 (VA - VHA) awarded a $307,114.91 purchase order to Cardinal Health, Inc., doing business as Cardinal Health, for emergency TECARTUS infusion services. Cardinal Health, Inc. will provide these services as the prime contractor from April 25, 2023 through May 3, 2023 in Dublin, Ohio under a firm fixed price contract structure. No subcontractors were identified.</p>
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 8 (VA - VHA) awarded a $307,114.91 purchase order to Cardinal Health, Inc., doing business as Cardinal Health, for EMERGENCY QTY 1 TECCARTUS. The prime contractor, Cardinal Health, Inc., a subsidiary of Cardinal Health, will provide the biopharmaceutical product Teccartus from its facility in Dublin, Ohio over a period of approximately three months, from September 13, 2023 through November 24,...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 8 (VA - VHA) awarded a $287,923.29 purchase order to Cardinal Health, Inc., doing business as Cardinal Health, for emergency order of Yescxart drugs in the quantity of one. The prime contractor, Cardinal Health, Inc., a subsidiary of Cardinal Health, Inc., will provide the drugs from its Dublin, Ohio facility between April 20, 2022 and April 26, 2022 under firm fixed pricing terms. No applicable...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 10 (VA-VHA) awarded Gilead Sciences Inc., doing business as Gilead, a $393,104.70 delivery order under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) master contract to provide YESCARTA pharmaceuticals. The place of performance is La Vergne, Tennessee and the period of performance is July 8, 2022 through September 30, 2022. The contract utilizes firm fixed pricing. YESCARTA is...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 8 awarded a $13,833 purchase order to Cardinal Health 414, LLC Nphs Division for an emergency dose of Xofigo. As the parent company, Cardinal Health, Inc. will support delivery of the radioactive therapeutic pharmaceutical to the VA medical center in Dublin, Ohio by the end of November 2023. The firm fixed price contract utilizes no set-aside designations and does not specify any major...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 2 awarded a $153,947.27 firm fixed price delivery order to Cardinal Health 414, LLC for radiopharmaceutical products and services. As the prime contractor, Cardinal Health 414 is a division of Cardinal Health, Inc., a major medical products and services provider. This order was awarded on December 1, 2020 with a completion date of November 30, 2021 to support the VA's healthcare programs in...

The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 19 (VA-VHA) awarded a $287,923.29 purchase order contract to Cardinal Health, Inc. for YESCARTA Therapy. As the prime contractor, Cardinal Health Inc. Division - doing business as Cardinal Health, will provide YESCARTA Therapy from August 18, 2022 through February 28, 2023 in Dublin, Ohio under firm fixed pricing terms. YESCARTA is a chimeric antigen receptor (CAR) T-cell immunotherapy manufactured by Kite Pharma, Inc., a subsidiary of Gilead Sciences, Inc., for the treatment of certain types of non-Hodgkin lymphoma. Cardinal Health will likely serve as a distributor for this therapy without conducting research and development activities itself.

Generated 11/28/23, 2:10 AM